再极医药
RESEARCH research to save life
Maxinovel Pharmaceuticals is a high-tech biomedical company,focusing on targeted therapy and immunotherapy with First-in-class drug research.

We claim that "research to save life, give hope for life", and with the goal of combined tumor immunity, targeted therapy as well as chemotherapeut. We will bring new therapies to more cancer patients.
MORE+
Maxinovel Pharmaceuticals is the second company (after Incyte, US the Global 500 (S&P500),) to publish a head-to-head activity comparison of oral PD-L1 inhibitors with biomacromolecular antibody drugs at AACR.
ACHIEVEMENTS Maxinovel Pharma presented in the 2019 AACR the head to head comparison of its orally active small molecule PD-L1 inhibitor with commercially marketed PD-L1 antibody drug Durvalumab in the human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice model [LB-018]. These two molecules demonstrated similar tumor growth inhibition (TGI) when they were tested twice. DETAIL
LATEST DEVELOPMENTS
CONTACT US
Please leave us a message,
we will reply to you as soon as possible, thank you!
再极医药
RESEARCH research to save life
Maxinovel Pharmaceuticals is a high-tech biomedical company, focusing on targeted therapy and immunotherapy with First-in-class drug research.

We claim that "research to save life, give hope for life", and with the goal of combined tumor immunity, targeted therapy as well as chemotherapeut. We will bring new therapies to more cancer patients.
MORE+
Maxinovel Pharmaceuticals is the second company (after Incyte, US the Global 500 (S&P500),) to publish a head-to-head activity comparison of oral PD-L1 inhibitors with biomacromolecular antibody drugs at AACR.
ACHIEVEMENTS Maxinovel Pharma presented in the 2019 AACR the head to head comparison of its orally active small molecule PD-L1 inhibitor with commercially marketed PD-L1 antibody drug Durvalumab in the human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice model [LB-018]. These two molecules demonstrated similar tumor growth inhibition (TGI) when they were tested twice. DETAIL
LATEST
DEVELOPMENTS
CONTACT US
Please leave us a message,
we will reply to you as soon as possible, thank you!